Quantcast

Latest immunotherapies Stories

2014-07-16 04:21:39

TUEBINGEN, Germany, July 16, 2014 /PRNewswire/ -- Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics' Human Immunopeptidome Program to identify the most relevant targets for cancer immunotherapies immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer, today announces that it has...

2014-07-10 08:27:19

SEOUL, South Korea, BUSAN, South Korea and SAN FRANCISCO, July 10, 2014 /PRNewswire/ -- SillaJen, Inc., a privately-held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer, announced today a publication that reviews data from the company's oncolytic immunotherapy program, including its lead product Pexa-Vec. Additionally, the publication outlines the rationale for combination therapy with other cancer immunotherapies, such as...

2014-06-30 12:29:20

Immune Checkpoint Inhibitors Will Hold an Impressive 85 Percent Market Share, According to Findings from Decision Resources Group BURLINGTON, Mass., June 30, 2014 /PRNewswire/ -- Decision Resources Group finds that the immunotherapy market will experience considerable growth through 2022, increasing from $1.1 billion in 2012 to nearly $9 billion in 2022 (corresponding to 23.8 percent annual growth) in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. This impressive...

2014-06-10 12:30:30

LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Non-small cell lung cancer: Game changing immunotherapies to revolutionise treatment - KOL Insighthttp://www.reportbuyer.com/pharma_healthcare/diseases/non_small_cell_lung_cancer_game_changing_immunotherapies_revolutionise_treatment_kol_insight.html Change is coming to the NSCLC treatment algorithm--and it's coming soon. Revolutionary new immunotherapies, more personalised treatment choices...

2014-04-28 16:29:03

IPSWICH, Mass., April 28, 2014 /PRNewswire/ -- New England Biolabs (NEB(®)) announces that it has been awarded a $250,000 grant from the Massachusetts Life Sciences Center (MLSC) to fund a collaboration with Transgene, a French biopharmaceutical company developing innovative immunotherapies for oncology and infectious diseases. http://photos.prnewswire.com/prnvar/20090921/NE79207LOGO-b The collaboration between NEB and Transgene involves an innovative approach to enzymatically...

2014-04-24 08:33:57

Leading Cancer Immunotherapy Startup also Bolsters Leadership Team with Two Key Appointments SEATTLE, April 24, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, a biotechnology company focused on bringing forward novel immunotherapies for cancer, today announced the close of its Series A round with $176M in fully committed funds. http://photos.prnewswire.com/prnvar/20140113/DC45426LOGO Juno's initial funding of $120 million came predominantly from leading technology venture...

2014-04-02 23:32:49

Presentation details three separate tuberculosis immunotherapies developed by Immunitor in collaboration with academic institutions and private companies in Mongolia, China, Thailand, Ukraine, UK, USA and Canada. Data presented support the Immunitor strategy to target inflammation as the main cause of TB and development of immunomodulators and therapeutic vaccines which demonstrate ability to rapidly clear TB, including MDR-TB and TB with HIV. Vancouver, BC, Canada (PRWEB) April 02, 2014...

2014-03-20 23:31:05

MedVax Technologies, Inc., a biopharmaceutical company developing and commercializing cancer vaccine immunotherapies, announced today that Robert Brooks, Chief Executive Officer, will be presenting a company overview at the 6th Annual Biotech Showcase investor and partnering conference. Miami, FL (PRWEB) March 20, 2014 MedVax Technologies, Inc., a biopharmaceutical company developing and commercializing cancer vaccine immunotherapies, announced today that Robert Brooks, Chief Executive...

2014-03-19 20:21:22

-- Collaboration Focused on Cancer Immunotherapies for Pets -- KANSAS CITY, Kan., and PRINCETON, N.J., March 19, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced a global...

2014-03-06 13:13:25

Ludwig researchers show that infecting just 1 tumor with a virus could boost the systemic effectiveness of cancer immunotherapy A Ludwig Cancer Research study suggests that the clinical efficacy of checkpoint blockade, a powerful new strategy to harness the immune response to treat cancers, might be dramatically improved if combined with oncolytic virotherapy, an investigational intervention that employs viruses to destroy tumors. Published today in the journal Science Translational...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related